Meningococcal Vaccinations
Tóm tắt
Từ khóa
Tài liệu tham khảo
Stephens DS, Apicella MA. Neisseria meningitidis. In: Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 8th ed. Philadelphia, PA Elsevier Saunders Inc.; 2015. p. 2425-45.
Marchiafava E, Celli A. Spra i micrococchi della meningite cerebrospinale epidemica. Gazz degli Ospedali. 1884;5:59.
Weichselbaum A. Ueber die aetiologie der akuten meningitis cerebrospinalis. Fortschr Med. 1887;5:573.
Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:853–61.
Goldschneider I, Gotschlich EC, Artenstin MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969;129:1327–48.
Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus, I. The role of humoral antibodies. J Exp Med. 1969;129:1307–26.
Stephens DS. Uncloaking the meningococcus, the dynamics of meningococcal carriage and meningococcal disease. Lancet. 1999;353:941–2.
Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344:1378–88.
Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30(Suppl 2):B3–9.
Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine. 2006;24:4692–700.
Thigpen MC, Whitney CG, Messonnier NE, et al. Emerging infections programs network. bacterial meningitis in the United States, 1998–2007. N Engl J Med. 2011;364:2016–25.
Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev. 2010;23:467–92.
WHO Initiative for Vaccine Research (IVR): Meningococcal disease. Available at http://www.who.int/vaccine_research/diseases/soa_bacterial/en/index1.html . Accessed 1 Feb 2016.
Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec. 2011;86:521–39.
Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin Infect Dis. 2001;33:737–9.
Edwards MS, Baker CJ. Complications and sequelae of meningococcal infections in children. J Pediatr. 1981;99:540–5.
Gianchecchi E, Torelli A, Piccini G, Piccirella S, Montomoli E. Neisseria meningitidis infection: who, when and where? Expert Rev Anti Infect Ther. 2015;13:1249–63.
Ashton FE, Ryan A, Diena B, et al. A new serogroup (L) of Neisseria meningitidis. J Clin Microbiol. 1983;17:722–7.
Abio A, Neal KR, Beck CR. An epidemiological review of changes in meningococcal biology during the last 100 years. Pathog Glob Health. 2013;107:373–80.
Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev. 2007;31:101–7.
Halperin SA, Bettinger JA, Greenwood B, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30(Suppl 2):B26–36.
Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51–63.
European Centre for Disease Prevention and Control. Surveillance of Invasive bacterial diseases in Europe 2008/2009. Stockholm: ECDC; 2011.
Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015;60:578–85.
Ceyan M, Anis S, Htun-Myint L, et al. Meningococcal disease in the Middle East and North Africa: an important public health consideration. Int J Infect Dis. 2012;16:e574–82.
Sáfadi MA, González-Ayala S, Jäkel A, et al. The epidemiology of meningococcal disease in Latin America, 1945–2010: an unpredictable and changing landscape. Epidemiol Infect. 2012;141:447–58.
Vyse A, Wolter JM, Chen J, et al. Meningococcal disease in Asia: an under-recognised public health burden. Epidemiol Infect. 2011;139:967–85.
Lucidarme J, Hill DM, Bratcher HB, et al. Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage. J Infect. 2015;71:544–52.
Mustapha MM, Marsh JW, Harrison LH. Global epidemiology of capsular group W meningococcal disease (1970–2015): multifocal emergence and persistence of hypervirulent sequence type (ST)-11 clonal complex. Vaccine. 2016;34:1515–23.
Zhou H, Liu W, Xu L, et al. Spread of Neisseria meningitidis serogroup W clone, China. Emerg Infect Dis. 2013;19:1496–9.
Mandal S, Wu HM, MacNeil JR, et al. Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States. Clin Infect Dis. 2013;57:344–8.
Soeters HM, McNamara LA, Whaley M, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college—Rhode Island, 2015. MMWR. 2015;64:606–7.
Cohn A, MacNeil J. The changing epidemiology of meningococcal disease. Infect Dis Clin N Am. 2015;29:667–77.
Centers for Disease Control and Prevention. Meningococcal Disease: Technical & Clinical Information. http://www.cdc.gov/meningococcal/clinical-info.html . Accessed 20 Feb 2016.
Mutonga DM, Pimentel G, Muindi J, et al. Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005–2006. Am J Trop Med Hyg. 2009;80:619–24.
Ram S, Lewis LA, Rice PA. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev. 2010;23:740–80.
Miller EC, Chase NM, Densen P, et al. Autoantibody stabilization of the classical pathway C3 convertase leading to C3 deficiency and neisserial sepsis: c4 nephritic factor revisited. Clin Immunol. 2012;145:241–50.
Struijk GH, Bouts AHM, Rijkers GT, et al. Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant. 2013;13:819–20.
Salit IE. Meningococcemia caused by serogroup W-135: association with hypogammaglobulinemia. Arch Intern Med. 1981;141:664–5.
Miller L, Arakaki L, Ramautar A, et al. Elevated risk for invasive meningococcal disease among persons with HIV. Ann Intern Med. 2014;160:30–7.
Simon MS, Weiss D, Gulick RM. Invasive meningococcal disease in men who have sex with men. Ann Intern Med. 2013;159(4):300–1.
Emonts M, Hazelzet JA, de Groot R, Hermans PW. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect Dis. 2003;3:565–77.
Hibberd ML, Sumiya M, Summerfield JA, et al. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Lancet. 1999;353:1049–53.
Fijen CA, Bredius RG, Kuijper EJ, et al. The role of Fc gamma receptor polymorphisms and C3 in the immune defense against Neisseria meningitidis in complement-deficient individuals. Clin Exp Immunol. 2000;120:338–45.
Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50:184–91.
Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk factors for meningococcal disease in college students. JAMA. 2001;286:688–93.
Cohn AC, MacNeil JR, Clark TA, et al; Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-2):1–28.
Sejvar JJ, Johnson D, Popovic T, et al. Assessing the risk of laboratory-acquired meningococcal disease. J Clin Microbiol. 2005;43:4811–4.
Aguilera J-F, Perrocheau A, Meffre C. Hahné S; W135 Working Group. Outbreak of the serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg Infect Dis. 2002;8:761–7.
Moore PS, Hierholzer J, DeWitt W, Gouan K, et al. Respiratory viruses and mycoplasma as cofactors for epidemic group A meningoccal meningitis. JAMA. 1990;264:1271–5.
Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J. 1997;16:979–83.
Molesworth AM, Cuevas LE, Connor SJ, et al. Environmental risk and meningitis epidemics in Africa. Emerge Infect Dis. 2003;9:1287–93.
Greenwood BM, Bradley AK, Wall RA. Meningococcal disease and season in sub-Saharan Africa. Lancet. 1985;2:829–30.
Artenstein MS, Gold R, Zimmerly JG, et al. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med. 1970;282:417–20.
Vipond C, Care R, Feavers IM. History of meningococcal vaccines and their serological correlates of protection. Vaccine. 2012;30:B10–7.
Borrow R. Advances with vaccination against Neisseria meningitidis. Trop Med Int Health. 2012;17:1478–91.
Micoli F, Romano MR, Tontini M, et al. Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X. Proc Natl Acad Sci USA. 2013;1110:19077–82.
Holst J, Oster P, Arnold R, et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother. 2013;9:1241–53.
Caron F, du Châtelet IP, Leroy JP, et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis. 2011;11:455–63.
Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR, Centers for Disease Control (CDC). Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the advisory committee on immunization practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:608–12.
Kim DK, Bridges CB, Harriman KH, on behalf of the Advisory Committee on Immunization Practices. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States, 2016. Ann Intern Med. 2016;164:184–94.
Australian Immunisation Handbook. Australian Government Department of Health. 4.10 Meningococcal disease. Available at http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home~handbook10part4~handbook10-4-10#list4-10-1 . Accessed 21 Feb 2016.
Joint Committee on Vaccination and Immunisation. Available at https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation . Accessed 21 Feb 2016.
Green Book: Chapter 7 Immunization of Individuals with Underlying Medical Conditions; p. 49–56. Available at https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/309218/Green_Book_Chapter_7_v1_3.pdf . Chapter 22 Meningococcal; p. 1–29. Available at https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/462629/2904512_Green_Book_Chapter_22_v6_0W.PDF . Chapter 12 Immunisation of healthcare and laboratory staff; p. 83–90. Available at https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/147882/Green-Book-Chapter-12.pdf .
Geretti AM; BHIVA Immunization Writing Committee. British HIV Association guidelines for immunization of HIV-infected adults 2015. British HIV Association 2015. Available at http://www.bhiva.org/documents/Guidelines/Vaccination/2015-Vaccination-Guidelines.pdf .
Public Agency of Canada-Canada Immunization Guide. Available at www.publichealth.gc.ca . Accessed 21 Feb 2016.
Maiden MC, Ibarza-Pavon AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197:737–43.
Daugla DM, Gami JP, Gamougam K, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study. Lancet. 2014;383:40–7.
Okwo-Bele J-M, LaForce FM, Borrow R, Preziosi M-P. Documenting the results of a successful partnership: a new meningococcal vaccine for Africa. Clin Infect Dis. 2015;61:S389–90.
WHO Weekly epidemiological record-Meningococcal A conjugate vaccine: updated guidance, February 2015;90, 57–68. Available at http://www.who.int/wer/2015/wer9008.pdf?ua=1 .
Centers for Disease Control and Prevention. Infant meningococcal vaccination: advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR Morb Mortal Wkly Rep. 2013;62:52–4.
Al-Tawfiq JA, Memish ZA. The Hajj: updated health hazards and current recommendations for 2012. Euro Surveill. 2012;17. pii: 20295.
Cramer JP, Wilder-Smith A. Meningococcal disease in travelers: update on vaccine options. Curr Opin Infect Dis. 2012;25:507–17.
Borrow R, Joseph H, Andrews N, et al. Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults. Vaccine. 2000;19:1129–32.
Richmond P, Kaczmarski E, Borrow R, et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis. 2000;181:761–4.
MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of Serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:1171–6.
McNamara LA, Shumate AM, Johnsen P, et al. Use of a serogroup B meningococcal vaccine in the US in response to a university outbreak. Pediatrics. 2015;135:798–804.
Pollard AJ, Riordan A, Ramsay M. Group B meningococcal vaccine: recommendations for UK use. Lancet. 2014;383:1103–4.
Gossger N, Snape MD, Yu LM, et al. European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307:573–82.
Vesikari T, Esposito S, Prymula R, et al. EU Meningococcal B Infant Vaccine Study group. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381:825–35.
Vaccine Schedule. The European Centre for Disease Prevention and Control. Available at: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx . Accessed on 4 Jan 2016.
Campbell H, Saliba V, Borrow R, Ramsay M, Ladhani SN. Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015. Euro Surveill. 2015;20. pii: 21188.
Safadi MA, Bettinger JA, Moreno Meturana G, et al. Evolving meningococcal immunization strategies. Expert Rev Vaccines. 2015;14:505–17.
Harrison LH, Shutt KA, Schmink SE, et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era—United States, 2000–2005. J Infect Dis. 2010;201:1208–24.
Academy of Pediatrics Committee on Infectious Diseases. Updated recommendations on the use of meningococcal vaccines. Pediatrics. 2014;134:400.
Balmer P, Falconer M, McDonald P, et al. Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals. Infect Immun. 2004;72:332–7.
Lujan-Zilbermann J, Warshaw MG, Williams PL, International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1065 Protocol Team, et al. Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus. J Pediatr. 2012;161:676–81.
American Academy of Pediatrics. [Meningococcal Infections.] In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village: American Academy of Pediatrics; 2015. p. 547–57.
Gasparini R, Tregnaghi M, Keshavan P, Ypma E, Han L, Smolenov I. Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine and commonly administered vaccines after coadministration. Pediatr Infect Dis J. 2016;35:81–93.
Food and Drug Administration. Product approval information: package insert. Menactra (meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine). Sanofi Pasteur. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2011. Available at http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm131170.pdf . Accessed 21 Feb 2016.
Centers for Disease Control and Prevention: Recommended Immunization Schedules for Persons Aged 0 Through 18 years; United States 2016. Available at: http://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf . Accessed 22 Feb 2016.
Weston WM, Friedland LR, Wu X, Howe B. Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration. Vaccine. 2011;29:1017–22.
Zahlanie YC, Hammadi MM, Ghanem ST, Dbaibo S. Review of meningococcal vaccines with updates on immunization in adults. Hum Vaccin Immunother. 2014;10:995–1007.
Velentgas P, Amato AA, Bohn RL, et al. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf. 2012;21:1350–8.
De Wals P, Deceuninck G, Boucher RM, Ouakki M. Risk of Guillain-Barrè syndrome following serogroup C meningococcal conjugate vaccine in Quebec, Canada. Clin Infect Dis. 2008;46:e75–7.
Zheteyeva Y, Moro PL, Yue X, Broder K. Safety of meningococcal polysaccharide-protein conjugate vaccine in pregnancy: a review of the vaccine adverse event reporting system. Am J Obstet Gynecol. 2013;208:e1–6.
Toxnet [Internet]. Bethesda (MD): National Library of Medicine (US): [Last Revision Date Mar 10, 2015]. Meningococcal Vaccines; LactMed Record Number: 168 [about 3 p]. Available at: http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@term+@DOCNO+168 .
Anonymous. Meningococcal disease. Secondary attack rate and chemoprophylaxis in the United States, 1974. JAMA. 1976;235:261–5.
Zalmanovici Trestioreanu A, Fraser A, Gafter-Gvili A, Paul M, Leibovici L. Antibiotics for preventing meningococcal infections. Cochrane Database Syst Rev. 2011; CD004785.
Jorgensen JH, Crawford SA, Fiebelkorn KR. Susceptibility of Neisseria meningitidis to 16 antimicrobial agents and characterization of resistance mechanisms affecting some agents. J Clin Microbiol. 2005;43:3162–71.
Prasad K, Karlupia N. Prevention of bacterial meningitis: an overview of Cochrane systematic reviews. Respir Med. 2007;101:2037–43.
Schwentker FF, Gelman S, Long PH. The treatment of meningococcal meningitis with sulfonamide: preliminary report. JAMA. 1937;108:1407–8.